FORM PTO-1449 (modified) To: U.S. D partment of Commerce (PW FORM PAT-1449)								Atty. Dkt. No.		Clie	Client Ref.				
		rademark Office	(007 Ž	242	003 (C) 4 4									
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \								0275537				8-30-	0524A		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT									Applicant: GRILLO-LOPEZ et al.						
								Appln. No.: 09/436,348							
\									e: November 9, 1	999					
Date: Octol			Page	1	of	1	<u> </u>	Examiner	R. Schwadron	Gro	up Art l	Jnit: 1	644		
U.S. PATE	<u>ם דוף</u>	OCUMENTS													
Examiner's		Document \		Date		Name				Clas			Filing		
Initials*		Number	\	MM/Y	YYY	(Family N	lame	of First Inv	entor)	ĺ	Cla	SS	Date		
	AR	5,530,101	+-	06/10	DE .	Queen et	21			_			(if approp	riate)	
		5,225,539		06/1996 07/1993		Winter et				 			 		
		4,816,397 4,816,567		03/1989		Boss et al. Cabilly et al.			 			 			
-												 			
		5,500,362		Q3/1989 Q3/1996		Robinson et al.									
		5,736,137		04/1988								+			
		6,183,744		02/2001		Anderson et al. Goldenberg							 		
				10/20									 		
	IR	6,306,393		10/20	101	Goldenbe	er g			ļ	_		 		
	JR				/										
	KR				+	 			·		+		ļ <u> </u>		
	LR				+								 		
	MR I			-	\	-							──		
	NR			\vdash	7	\							├──		
				<u> </u>		/							 	•	
FOREIGN	EIGN PATENT DOCUMENTS									English Abstract		Translation Readily			
		Document Date Number MM/Y		Coun		try Inven		tor Name					Available	Available	
		Number	IAUAN I	• • •		\					Fastass	1100	<u> </u>	I	
	20		-	-							Enclosed	INO	Enclose	NO	
	OR PR		 		-	$\overline{}$		-				$+\!-$	 	╁	
			 		-	+	-					+	├──	╁—	
	QR		\vdash		-		-			-		┼	 	╁┈	
	RR		├──				ackslash					+	 	⊢	
	SR		 		 		\vdash	-				$+\!-$	 	┢	
	rr ID		├		 		1					+-	 	-	
	JR 10		├─		_		\vdash					 	 	⊢	
	/R		<u> </u>	T'44	<u></u>		<u> </u>	10						╄╼	
		ng in this order A										<u> </u>	<u> </u>	<u> </u>	
ſ		McLaughlin et al., Rituximab® chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent													
		lymphoma: half of patients respond to a 4-dose treatment program, (1998), <i>J Clin Oncology</i> , 16:2825-2833.													
ľ	\r	R McLaughlin et al., Efficacy controls in long-term follow-up patients treated with rituximab for relap refractory, low-grade or follicular NHL, (1998), Blood, 92:414a-415a.										sea or			
									ells and clinical a	ctivity	in NHI	/100)8) <i>Bl</i> o		
		92(10 suppl 1):3		JAIIIIG	D. OUI	relation be	.twcc	i eneciol d	cus and curucara	Cuvity	III INITE	., (133	, DIO	ου,	
				notyp	ic CD2	20+ and C	D19+	B cells in	eripheral blood o	f patie	ents wit	h mul	tiple		
	ļ	Rottenburger et al., Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation, (1999), Br J Haematol.,													
	_	106(2):545-552.							\						
Examin r								Date Cons							
*EXAMINER		Initial if citation co	nsidere	d, wh	ther or	not citation	n is in	conformanc	e with MPEP § 609	. Drav	w line th	rough	citation i	if	
HOLIH CONTOR	nanc	e and not conside	rea. Inc	inge ci	opy of	this form w	th nex	<u>t communic</u>	ation to Applicant.						

00 hotions/2003/